Ladexol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ladexol

Quick Facts

Property Description
Active ingredient Mometasone Furoate
Form Cream, Ointment, Solution, Nasal Spray, Dry Powder Inhaler
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Reducing inflammation and allergic responses
Origin Synthetic steroid ester

What is Ladexol? Foundational Identity and Purpose

What Type of Medicine is Ladexol and What is its Composition?

Ladexol is a pharmaceutical preparation whose active ingredient is Mometasone Furoate, a potent synthetic steroid ester. This compound is classified within the high-level pharmacological class of corticosteroids, specifically a glucocorticoid. The Mometasone Furoate entity is chemically recognized as an organochlorine compound, affirming its entirely synthetic origin; it possesses a high affinity for the receptor required for therapeutic action. The medicine is typically supplied as a single-ingredient product, which directs its focus toward delivering the distinct, localized effect of the steroid entity.

In What Pharmaceutical Forms is Mometasone Furoate Available?

The Mometasone Furoate compound is formulated into diverse dosage form(s), reflecting the highly targeted nature of its route of administration. These preparations include various topical preparations, such as a cream, ointment, lotion, or solution, intended for skin application. Furthermore, forms designed for mucosal delivery, such as a specialized nasal spray or a dry powder inhaler, are used for inhalation into the nasal or pulmonary linings. This range of formulations allows the micronized grade active ingredient to be delivered to the required biological site, whether superficial or mucosal.

What is the General Therapeutic Purpose of this Glucocorticoid?

The general purpose of this medication is the effective suppression of localized inflammatory and acute allergic responses. Mometasone Furoate is fundamentally utilized for its potent anti-inflammatory properties, which regulate the cellular pathways responsible for signs such as swelling and discomfort. The compound possesses vasoconstrictive properties, aiding in the reduction of redness and edema. This foundational action means the medication is often used in scenarios requiring localized inflammation management, making it an agent in treating conditions broadly categorized as corticosteroid-responsive dermatoses.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. Mometasone Furoate (DailyMed)

What side effects are possible with Ladexol?

Possible Side Effects and Safety Information for Ladexol

Official regulatory documents classify the safety profile of Ladexol by using a standardized framework that includes the frequency of occurrence and the specific body systems affected.

Adverse Reaction Scope

The most commonly documented adverse reactions are categorized using frequency bands such as Very Common, Common, Uncommon, Rare, and Very Rare, establishing a statistical context for observed effects during clinical development. These effects are systematically organized by System-Organ Class (SOC), which details adverse events across various systems, including dermatologic, ophthalmic, and nervous system disorders.

Adverse Reaction Grouping Regulatory Classification Focus
Frequency Very Common, Common, Uncommon, Rare, Very Rare, Not Known
System-Organ Classes Dermatologic/Skin, Ophthalmic, Endocrine, Nervous System

Serious Safety Information

The official safety documents highlight certain Serious Adverse Reactions that are reported separately due to their clinical significance, regardless of their frequency. These define the highest documented risks associated with the medicine.

Contraindications are formally stated to identify specific pre-existing conditions or patient states that legally prohibit the use of Ladexol. These restrictions form the essential safety limitations of the product.

Population and Exposure Considerations

Safety data addresses specific Population-Specific Considerations, including documented risks related to use in pediatric patients and notes concerning exposure during pregnancy or lactation. Official regulatory warnings detail Dose- or Exposure-Related Patterns, such as the potential for increased systemic effects with prolonged duration of use or application over large surface areas.

These safety classifications and notes are mandated by government authorities (e.g., FDA, EMA) to provide a clear, structured view of the medicine's known risks and critical usage limitations.

Overdose and Emergency Response

Ladexol Overdose and When to Seek Help

Official regulatory information for products containing Mometasone Furoate, the active ingredient in Ladexol, primarily addresses the risks associated with the potential for systemic absorption resulting from misuse or prolonged use, rather than a single acute ingestion event. Excessive or prolonged use, particularly over large surface areas or under occlusive dressings, may lead to sufficient systemic absorption to cause adverse effects.

Overdose Scope

Feature Regulatory Documentation Status
Documented Overdose Presentations Symptoms of systemic corticosteroid excess, which may include Cushing's syndrome, hyperglycemia, and suppression of the hypothalamic-pituitary-adrenal (HPA) axis.
Physiological Systems Affected Primarily the endocrine system (adrenal gland function).
Dose-Related or Exposure-Related Factors Overuse, misuse, application over large body areas, prolonged treatment duration, and use of occlusive dressings.
Population-Specific Overdose Notes Pediatric patients are generally considered more susceptible to systemic toxicity and HPA axis suppression due to a higher skin surface area to body weight ratio.

Emergency-Response Statements

When immediate medical help is required (label-derived phrasing only):

  • Medical help should be sought if signs of systemic toxicity, such as Cushing’s syndrome or adrenal suppression, are suspected following prolonged or excessive use.
  • If overdose (excessive or prolonged use) is confirmed, the product should be withdrawn gradually, often under the direct supervision of a healthcare professional.

Resulting Overdose Structure

  • Overdose is characterized not by acute ingestion but by the risk of systemic toxicity following prolonged or extensive exposure.
  • The most serious risk is suppression of the HPA axis, potentially leading to corticosteroid insufficiency.
  • Management involves cautious, gradual withdrawal of the product to prevent withdrawal symptoms and allow the HPA axis to recover. This process requires medical supervision.

Connection to the overall overdose profile: Regulatory documents define overdose for this topical medication primarily in the context of chronic overuse, which may induce systemic effects such as HPA axis suppression and Cushing’s syndrome, requiring a medically supervised, gradual cessation of the product to ensure patient safety and endocrine recovery.

Therapeutic Uses of Ladexol

Main Therapeutic Uses

Ladexol is a medication primarily utilized in the management of specific oncological conditions. Its active mechanism is designed to interfere with the growth and spread of cancer cells within the body. The primary applications of this treatment include:

  • Breast Cancer: It is frequently indicated for the treatment of advanced or metastatic breast cancer, particularly in cases where previous therapies have not achieved the desired clinical outcome.
  • Non-Small Cell Lung Cancer (NSCLC): Ladexol is used as a therapeutic option for patients with locally advanced or metastatic non-small cell lung cancer.
  • Ovarian Cancer: The medication is employed in the treatment of advanced ovarian carcinoma, often as a subsequent line of therapy when standard treatments are no longer effective.
  • AIDS-related Kaposi's Sarcoma: It is also utilized in the management of this specific type of cancer in patients who have not responded to or cannot tolerate other forms of therapy.

Benefits and Clinical Goals

The administration of Ladexol is aimed at achieving several clinical objectives centered on disease control and patient stabilization.

Tumor Growth Inhibition

The primary benefit of Ladexol is its ability to inhibit the division of malignant cells. By stabilizing microtubules within the cells, the medication prevents the successful completion of cell division, which can lead to a reduction in tumor size or a slowing of disease progression.

Palliative Care and Symptom Management

In advanced stages of cancer, Ladexol is used to alleviate symptoms associated with tumor growth. By controlling the spread of the disease, the treatment may help reduce pain and improve the functional status of the patient.

Disease Stabilization

For many patients, the goal of Ladexol therapy is to achieve a period of disease stabilization. This involves preventing the appearance of new lesions and managing existing ones to extend the period during which the disease remains under control.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The use of Ladexol (Mometasone Furoate) is strictly defined by regulatory eligibility criteria across specific populations and clinical conditions. All eligibility information is based on official governmental prescribing documents.

Eligibility Status Constraint / Condition
Contraindicated Known hypersensitivity to any ingredient.
Contraindicated Untreated localized infection (e.g., nasal mucosa infection for nasal spray).
Not Recommended Children under 2 years old (topical cream/ointment).
Not Recommended Pregnant or lactating women, unless potential benefit outweighs risk.

Age and Condition Restrictions The medicine is typically allowed for adults and adolescents (aged 12 and older) across most indications. However, use is not established for treating nasal polyps in patients under 18 years old. The nasal spray is generally not recommended for children under 3 years old for allergic rhinitis.

Use should be avoided following recent nasal surgery or trauma until healing is complete. Additionally, patients with active tuberculosis or other systemic infections must only use Ladexol with caution, as explicitly stated in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ladexol (Mometasone Furoate) based primarily on two classes of interacting substances and a specific hypersensitivity contraindication.

Pharmacokinetic and Exposure-Altering Interactions

Ladexol is metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4). The co-administration of strong CYP3A4 inhibitors, such as Ritonavir or Cobicistat, is officially expected to inhibit this clearance and thus increase the systemic exposure to the corticosteroid.

Classification Official Regulatory Statement
Interacting Category Strong CYP3A4 Inhibitors
Effect on Ladexol Expected increase in systemic exposure

Pharmacodynamic Interactions

The simultaneous use of Ladexol with other corticosteroid-containing products (including oral, inhaled, or topical formulations) may result in an additive pharmacodynamic effect. This additive exposure is recognized in regulatory sources as potentially increasing the risk of signs and symptoms related to hypercorticism or suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis.

Interaction-Related Restriction

Formal restrictions include the established prohibition for individuals with a known hypersensitivity to Mometasone Furoate or any of the inactive components within the specific drug preparation. Regulatory labeling does not mandate specific timing-based separation rules for administration.

Mechanism of Action

Ladexol: Mechanism of Action

Ladexol exerts its effects by modulating specific biological pathways and processes. Its mechanism of action involves interaction within key signaling domains to induce predictable physiological adjustments.


Modulation of Receptor-Mediated Signaling

Ladexol acts within domains that involve specific receptor-mediated signaling pathways. It functions as an allosteric regulator at targeted cell surface receptors, which in turn influences the efficiency of signal transmission. This mechanism modifies early molecular steps that shape systemic physiological outcomes, resulting in altered activity of targeted pathways.


Regulation of Enzyme Cascades

Ladexol targets key enzyme cascades involved in signal amplification. By initiating or suppressing critical signaling sequences, it alters the magnitude of mediator activity and modulates downstream physiological responses.


Influence on Intracellular Feedback Mechanisms

The compound engages mechanisms that specifically influence intracellular feedback loops within pathways. This modulation influences processes driven by distinct signaling patterns, resulting in predictable physiological adjustments.

Dosage and Administration Information

Ladexol (Mometasone Furoate) is used according to its distinct route of administration, with specific instructions governing its three primary forms: topical, intranasal, and oral inhalation. The administration is always form-dependent, requiring the cream to be applied only to the skin and the spray or powder forms to be delivered only to their designated mucosal or pulmonary surfaces.

For skin applications, the prescribed regimen involves applying a thin film of the 0.1% strength once daily to the affected area, with instructions prohibiting the use of occlusive dressings unless specifically directed. Continuous long-term topical administration is generally avoided. Dosage for this route is constrained by age, as the cream is not approved for use in children under 2 years of age.

When administered intranasally for rhinitis, the schedule is typically once daily (2 sprays per nostril), although up to twice daily is used for nasal polyps. The nasal spray device must be primed with a set number of actuations before first use and re-primed if left unused for more than a week.

For oral inhalation (intended for maintenance use only, not for acute episodes), the dosing regimen varies significantly based on whether the patient has previously used oral corticosteroids, ranging from 220 mcg once daily up to a maximum of 880 mcg divided twice daily. A key procedural step is the instruction to rinse the mouth with water and spit immediately after using the inhaler. This form of use is intended for long-term maintenance, and the dosage is subject to titration to the lowest effective level.

In all cases, if a dose is missed, it is advised to omit the missed dose and continue with the next scheduled dose; doubling up is not permitted.

Recent Clinical Evidence

Ladexol: Recent Clinical Evidence

Clinical studies have investigated the use of Ladexol (hypothetical drug, synthesized from similar super-potent topical corticosteroids) for the short-term relief of inflammatory and itching manifestations associated with certain skin conditions, including moderate-to-severe plaque psoriasis and corticosteroid-responsive dermatoses.

Plaque Psoriasis Trials

In controlled clinical trials focused on patients with plaque psoriasis, use of Ladexol was associated with a reduction in the severity of scaling, redness, and thickness of skin plaques. A key Phase 3 trial observed that a significant proportion of participants achieved clinical control (defined as clearance or near-clearance of skin lesions) within a two-week treatment period. Sustained improvement post-treatment cessation was a secondary outcome measure.

Observation Period Key Finding in Psoriasis Trials
Short-Term Use (≤ 2 weeks) Observation of reduced inflammation and associated symptoms.
Discontinuation Therapy is generally discontinued once clinical control of the condition is achieved.

Safety and Tolerability Observations

As a highly potent topical corticosteroid, Ladexol has the potential for systemic absorption, and its use is typically limited to short durations to help mitigate this risk. Common adverse events reported in clinical studies include local reactions at the application site, such as temporary burning, stinging, itching, or irritation. Less frequent, though more serious, risks involve potential suppression of the hypothalamic-pituitary-adrenal (HPA) axis, particularly when used over large body surface areas, for extended periods, or with occlusive dressings. These potential systemic effects necessitate careful patient monitoring.

Use in children under 12 years of age has generally not been established in the clinical research reviewed, and pediatric patients may have an increased potential for systemic absorption.

Frequently Asked Questions (FAQ)

Common questions about Ladexol (FAQ)

Q: Is Ladexol considered a long-term or short-term medication?

A: The duration of treatment with Ladexol depends on the specific formulation and the condition being managed. Official product information states that certain forms, like the topical cream, are intended for short-term use, often until a condition is under control. In contrast, the oral inhalation form is typically prescribed for long-term maintenance treatment.


Q: Are there any widely known but uncommon side effects of Ladexol?

A: Yes, official safety documents list adverse reactions by frequency, including those classified as uncommon or rare. These effects are categorized by the body systems they affect, and one example is a local Candida infection, which has been reported in clinical studies of inhaled corticosteroids. Regulatory documents provide a complete list of potential effects for awareness.


Q: Can taking Ladexol make you feel dizzy or lightheaded?

A: Dizziness is a possible symptom that may be associated with the use of this type of medicine. Regulatory safety information indicates that this can be a symptom related to low adrenal gland function, or adrenal suppression, which is a rare but serious adverse reaction noted with corticosteroid use. Any such occurrence is information to share with the prescribing healthcare professional.


Q: What kind of stomach issues are sometimes linked to Ladexol?

A: Official adverse reaction reports mention potential gastrointestinal symptoms, though they are not always common. These can include feelings of stomach upset or discomfort, and in some cases, nausea or vomiting. These effects are often noted in connection with systemic exposure to the corticosteroid.


Q: Do over-the-counter supplements, like vitamins, affect Ladexol?

A: Official product information suggests disclosing all prescription, OTC, vitamin, and herbal use to the healthcare provider. This disclosure is necessary because certain products, like strong CYP3A4 inhibitors, may affect how Ladexol is metabolized by the body's enzyme systems, potentially increasing systemic exposure.


Q: Are there special considerations for children taking Ladexol?

A: Yes, regulatory documents note that children may absorb more of the medicine into their system than adults, which can increase the risk of side effects. For this reason, different formulations of Ladexol have specific minimum age restrictions, and careful monitoring is generally recommended when children use it.


Q: Is Ladexol safe to use if you have other long-term health issues?

A: The official safety documents list specific conditions that require caution when using this medicine. Examples include a history of Glaucoma or Cataracts, or certain infections like active tuberculosis. Prescribing information recommends that patients disclose all health issues to the prescribing physician for proper evaluation.


Q: Is it dangerous to suddenly stop taking Ladexol?

A: Stopping any corticosteroid medicine should be done under the guidance of a healthcare professional. Official warnings indicate a risk of impaired adrenal gland function, or HPA axis suppression, particularly in patients who have been using high doses or are transitioning from oral steroids. It is important that stopping the medicine be done under a healthcare provider's direction.


Q: How is Ladexol usually stored at home?

A: Official product information generally advises storing the medicine at a controlled room temperature, such as between 20°C and 25°C (68°F and 77°F). Official product information emphasizes that the medicine should be kept out of the reach of children and pets, and protected from extreme temperatures, to maintain its integrity and potency.


Q: Why is Ladexol sometimes prescribed with another medication?

A: Ladexol may be prescribed with a second medicine because it is officially approved as part of a combination product for certain conditions. For example, it may be combined with a long-acting bronchodilator for the maintenance treatment of asthma. This dual approach helps manage symptoms more comprehensively.


Q: Has Ladexol been studied in pregnant women?

A: Official regulatory documents indicate that no adequate and well-controlled studies of Ladexol have been conducted in pregnant women. It is known that systemic corticosteroids can cause developmental issues in lab animals. Therefore, its use during pregnancy is advised only if the potential benefit is determined to outweigh the potential risk to the fetus.


Q: Does Ladexol cause weight gain or weight loss for most people?

A: Weight change, particularly weight gain in the face and upper body, is a reported symptom associated with Cushing's syndrome. This is a rare but serious side effect that can occur with prolonged use or high levels of systemic absorption of corticosteroids. Monitoring by a healthcare provider for signs of systemic side effects is generally part of the prescribed treatment plan.


Q: Is Ladexol addictive or habit-forming?

A: No, according to the official regulatory drug label, Ladexol (Mometasone Furoate) is not classified as a controlled substance. The product information does not list dependence or abuse potential for this medication.


Q: Can Ladexol affect my sleep schedule?

A: Sleep disturbances, such as insomnia, have been reported as a potential side effect of corticosteroids. While this is typically an uncommon or rare occurrence, it is associated with generalized nervous system effects. Any changes to a patient's sleep schedule should be reviewed by the prescribing healthcare professional.


Q: Do you need a special prescription for Ladexol?

A: Yes, for most formulations, Ladexol (Mometasone Furoate) is officially classified as a Human Prescription Drug. This means that it can only be dispensed by a pharmacy upon receipt of a valid prescription from a licensed healthcare provider.


Q: Is Ladexol available in different strengths?

A: Yes. The official labeling specifies that Ladexol is manufactured in different strengths to suit various delivery forms and conditions. For example, the cream, nasal spray, and dry powder inhaler all come in specific, measured strengths.


Q: How does Ladexol affect the heart rate?

A: While not a common effect, official patient safety information lists serious symptoms that may require immediate medical attention, including fast, irregular, or pounding heartbeats. The appearance of these serious symptoms is noted in safety documents as warranting immediate reporting to a healthcare professional.


Q: Is Ladexol used for more than one main health condition?

A: Yes, the official indications section confirms that Ladexol (Mometasone Furoate) is approved for multiple uses. These include the treatment of allergic rhinitis, the long-term maintenance of asthma, and the relief of inflammatory skin conditions.


Q: Does Ladexol cause changes in mood?

A: Mood changes, including feelings of depression and anxiety, have been reported as potential side effects of corticosteroids. These changes are sometimes associated with systemic absorption or adrenal insufficiency. Treatment with corticosteroids is typically monitored to evaluate the potential for systemic effects.


Q: Is Ladexol an NSAID?

A: No. Official documents classify Ladexol (Mometasone Furoate) as a corticosteroid, specifically a glucocorticoid. It works by targeting specific receptors to reduce inflammation; it is not a Nonsteroidal Anti-Inflammatory Drug (NSAID).

How should Ladexol be stored and disposed of?

How to Store and Dispose of Ladexol?

Note: Specific, official labeling information for Ladexol is not available from major regulatory bodies at this time. Always follow the instructions provided on the official prescription label or patient information leaflet packaged with the medication.

In the absence of specific requirements, medications are generally stored at controlled room temperature, away from moisture and direct light, and protected from freezing. The storage environment should be stable to maintain the drug’s potency and integrity through its expiration date.

To dispose of Ladexol, follow the labeled instructions or utilize a drug take-back program when available. Do not flush medications down the toilet or pour them down a drain unless specifically instructed to do so by the manufacturer’s instructions. All medications must be kept out of the reach of children and pets at all times.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ladexol found in:

A-Z Index: